A University of Cambridge spin-out company has raised £7 million in new funding, which will help in the development of treatments for liver and lung disease.
Scientists at the University of Cambridge have successfully created ‘mini-lungs’ using stem cells derived from skin cells of patients with cystic fibrosis, and have shown that these can be used to test potential new drugs for this debilitating lung disease.
Discovery could lead to new treatments for this genetic disorder.
Research paves the way for new approaches in the treatment of pulmonary arterial hypertension, a progressive lung disease that can lead to heart failure within three years.
Fundraising is under way for a joint Cambridge University and Papworth Hospital Heart and Lung Research Institute – to sit alongside the anticipated new Papworth Hospital on the Cambridge Biomedical Campus – enabling a major expansion of cardiorespiratory research in Cambridge.
A new collaboration based at the University of Cambridge will aim to discover and develop new medicines to treat liver disease.
New discoveries by Cambridge scientists about a molecular waste-disposal process that ‘eats’ bacteria are influencing the clinical management of cystic fibrosis, and could be the basis of innovative new treatments to fight off bacteria.